comparemela.com

Latest Breaking News On - Surveyor capital - Page 11 : comparemela.com

Frequency Therapeutics Inc (FREQ) Announces Merger and Private Placement of $117 Million

Post-merger, the combined company is expected to operate under the name Korro Bio, Inc.

Korro-bio
Ram-aiyar
Korro-bio-inc
Frequency-therapeutics-inc
Company-future
Nasdaq-capital-market
Surveyor-capital
Cormorant-asset-management
Chief-executive-officer
Nc
Cash-equivalents

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Cambridge
Cambridgeshire
United-kingdom
Israel
Massachusetts
United-states
Israeli
Davidl-lucchino
Tim-pearson
Nessan-bermingham
Ram-aiyar
Korro-bio

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to.

Cambridge
Cambridgeshire
United-kingdom
Israel
Massachusetts
United-states
Israeli
Piper-sandler
Nessan-bermingham
Tim-pearson
Ali-behbahani
Ram-aiyar

VYNE Therapeutics (VYNE) Announces Private Placement of $88 Million

VYNE Therapeutics (VYNE) Announces Private Placement of $88 Million
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David-domzalski
Lifesci-capital
Vyne-therapeutics-inc
Nasdaq
Access-biotechnology
Eventide-asset-management
Cormorant-asset-management
Acorn-bioventures
Parkman-healthcare-partners
Surveyor-capital
Soleus-capital
Palo-alto-investors

VYNE Therapeutics Announces Private Placement of $88 Million - VYNE Therapeutics (NASDAQ:VYNE)

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated

United-states
David-domzalski
Tyler-zeronda
John-fraunces
Lifesci-advisors
Nasdaq
Lifesci-capital
Exchange-commission
Therapeutics-inc
Altay-therapeutics
Access-biotechnology
Eventide-asset-management

vimarsana © 2020. All Rights Reserved.